UK markets close in 4 hours 48 minutes

Galecto, Inc. (GLTO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.38000.0000 (0.00%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.3800
Open3.4100
Bid0.0000 x 900
Ask0.0000 x 800
Day's range3.2600 - 3.4100
52-week range3.2600 - 17.9900
Volume122,000
Avg. volume151,137
Market cap85.385M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.8630
Earnings date09 Dec 2021 - 13 Dec 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.00
  • Globe Newswire

    Galecto to Present at Upcoming Investor Conferences

    BOSTON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Galecto’s management team will be presenting virtually at the Credit Suisse Healthcare Conference and in-person at the Jefferies London Healthcare Conference. Galecto’s management team will be available for 1x1 meetings at both of these conferences. Details for the presentations are below: Credi

  • Globe Newswire

    Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference

    BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, the Company’s Chief Executive Officer, will be presenting on Tuesday, September 28, 2021 at 8:40 AM ET and will be available for 1x1 meetings on the same date. A live audio webcast will be available on the "Webcasts & Presentations" section of Galecto’s Investor website at https:

  • Globe Newswire

    Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

    Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indicationsBOSTON, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed company focused on the development of novel treatments for fibrosis and cancer, today announced that the first patient has been treated with the galectin-3 inhibitor GB1211 in the Phase 1b/2a GULLIVER-2 trial. This trial marks the initiation of Galecto’s clinical program for GB1211 in l